LANXESS Aktiengesellschaft LXS.DE
Composite 36/100; the shares have moved about 60% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 8/100 — a strong mark against it.
Valuation ranks 65/100 — a moderate point in its favour. Growth ranks 53/100 — a slight point in its favour.
Quality ranks 8/100 — a strong mark against it. Momentum ranks 28/100 — a moderate mark against it. Income ranks 33/100 — a moderate mark against it.
What the company does LANXESS is a specialty chemicals group with three segments: Consumer Protection (disinfectants, hygiene), Specialty Additives (flame retardants, plasticizers), and Advanced Intermediates (agrochemical and pharma precursors).
Key financials Margins are weak: gross 19.7%, operating -2.9%, net -12.1%. Profitability metrics are negative (ROE -16.8%, ROA -1.1%, ROCE -2.8%) and leverage is elevated (Debt/Equity 0.72, Net debt/EBITDA 6.95). Revenue fell -13.9% while EPS surged 1374.2% on a small base.
Stock health Sideravia scores the stock Poor quality (Quality 12.7) but attractively valued (Valuation 76.6). Momentum is weak (12m -35.57%, RSI 55.40) and balance-sheet risk is high (Altman Z 0.96, Interest coverage -4.07).
Price vs fair value LANXESS trades at a discount to both our fair-value estimate and the average analyst target. - Trading 2.90% below our fair-value estimate of 16.36. - Trading 10.96% below the 12-month target of 17.64 (analyst count 14). - Forward EV/EBITDA 10.42 and P/B 0.38 signal valuation support. - Negative profitability (ROE -16.8%) contrasts with low valuation multiples.
Looking forward Forward P/E of 14.58 and FCF yield 43.3% suggest potential margin recovery, but weak momentum (12m -35.57%) and high leverage (Net debt/EBITDA 6.95) remain key risks.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.